Weight-Loss Injection: How GLP-1 Really Works
The weight-loss injection invents no new trick. It amplifies a natural satiety hormone. What lies behind it, where the effect is proven, and where its limits are.
Few topics in weight medicine move so many people right now as the weight-loss injection. Some celebrate it as a breakthrough, others distrust it as an artificial intervention. Both fall short. To place it properly, it helps to look at what the injection actually does: it mimics GLP-1, a hormone your own body makes after every meal.
This article explains the mechanism without cheering and without dismissing. It is about Ozempic and Wegovy (active ingredient semaglutide), about Mounjaro (active ingredient tirzepatide), and about why these medications act on the brain, stomach and blood sugar at the same time. Separate articles go deeper into side effects, into what happens after stopping, and into how you can support GLP-1 by natural means too. Here it is about the how.
I see the weight-loss injection neither as an enemy nor as a miracle cure. It is a real, effective tool. But a tool is only as good as the hand that guides it. Without foundations of nutrition, muscle and sleep, success often stays tied to the needle.
A hormone your body has long known
Many people imagine the weight-loss injection as something foreign that outwits the metabolism. That picture misses the point. The active ingredient docks onto the very same receptor that a natural hormone uses. To understand this, it helps to look at your gut.
In the lining of your gut sit special cells, the L-cells. As soon as food arrives, they release a hormone: GLP-1, glucagon-like peptide 1. The physiologist Jens Holst described this pathway in a classic review. GLP-1 is a messenger that tells the body: food is coming, get ready, and you will be full soon.
The special part: GLP-1 is broken down again extremely quickly. An enzyme called DPP-4 dismantles it within minutes. This is exactly where pharmacology comes in. The active ingredient of the injection is modified so that it escapes this rapid breakdown. According to the work of Timo Müller and colleagues, it therefore stays active not for minutes but steadily across the whole week. The pathway stays the same, only the signal lasts longer.
The weight-loss injection is no foreign-body trick. It amplifies a satiety signal your body sends anyway. The difference is not the what but the how long and how strong. A fleeting whisper after eating becomes a calm, lasting signal.
Why the injection acts in several places at once
A common misunderstanding is that the injection simply acts as an appetite suppressant in the stomach. In fact GLP-1 acts at several sites of the body at once. This very variety may explain why the effect on weight and metabolism can be so marked.
In the brain: the appetite control centre
GLP-1 receptors sit in brain regions that steer hunger and satiety. In a randomised study with functional imaging, a GLP-1 agent dampened activity in appetite and reward regions. Food loses part of its pull.
Via the vagus nerve: the satiety line
Part of the effect runs through the vagus nerve, the large data line between gut and brain. It reports satiety upward. A review describes these vagal fibres as a central route of the signal.
In the stomach: the brake
GLP-1 slows stomach emptying. The food stays longer in the stomach. The feeling of fullness lasts longer, and blood sugar rises more gently after eating.
In the pancreas: the blood-sugar fine-tuner
GLP-1 can improve the insulin response in a glucose-dependent way and dampen glucagon release. This can keep blood sugar steadier without pushing it dangerously low.
These four points of attack interlock. Hunger falls, satiety lasts longer, blood sugar swings less. A recent review summarises these central and peripheral routes and additionally describes effects on blood lipids and on inflammation in fat tissue.
Semaglutide and tirzepatide: what the studies show
Here the theory ends and the hard data begin. The efficacy of these medications is proven by large, randomised trials, meaning by the most reliable form of medical evidence.
In the STEP 1 trial, almost 2000 adults with obesity and without diabetes received either semaglutide 2.4 mg weekly or a placebo over 68 weeks, each on top of lifestyle support. Weight fell on average by 14.9 percent on semaglutide and by 2.4 percent on placebo. One in two treated people lost at least 15 percent. For you this means: the effect is real and at this magnitude hard to reach with tablets alone.
DOI: 10.1056/NEJMoa2032183In the SURMOUNT-1 trial, tirzepatide was studied, an agent that docks onto two receptors at once, GLP-1 and GIP. Across the different doses, a dose-dependent, marked weight reduction appeared, at the highest dose around a fifth of body weight. This means: a dual point of attack may amplify the effect even further.
DOI: 10.1056/NEJMoa2206038A review of incretin biology by Daniel Drucker and Jens Holst notes that GIP and GLP-1 together strengthen meal-stimulated insulin secretion, and that their receptors occur far beyond the pancreas, especially in the brain. This explains why the dual approach of tirzepatide is mechanistically plausible.
DOI: 10.1007/s00125-023-05906-7Semaglutide and tirzepatide lead to marked weight loss and better metabolic values in large randomised trials. The mechanism via the GLP-1 receptor is well-described physiology. This is solid evidence.
The range is wide. Some people respond strongly, others less so. How well it goes, in my view, always also depends on whether nutrition, exercise and sleep grow along with it. The injection alone rarely carries the whole way.
No miracle cure: what the injection cannot do
As clear as the effect is, so important is the honest framing of its limits. Anyone who sees the injection as self-running will be disappointed.
The weight can come back. In the follow-up to the STEP 1 trial, participants regained about two-thirds of the lost weight one year after stopping. This is no personal failure. It points to obesity being a chronic condition in which the body defends its old weight. How you can meet this rebound is covered in the article on stopping and the rebound effect.
In the SURMOUNT-4 trial with tirzepatide, continued treatment led to stable or further-falling weight, while switching to a placebo led to a marked rise again. This shows soberly: success is closely tied to continued treatment and to solid foundations.
DOI: 10.1001/jama.2023.24945Muscles can suffer too. With any larger weight loss, part of it comes from lean mass. A review classifies this loss under GLP-1 therapies as largely adaptive, meaning within the expected range. It matters above all in older people. Strength training and enough protein can protect the muscles during treatment.
A recent review of lean mass under GLP-1 therapies evaluates MRI data among other sources. The authors describe the muscle changes as largely adaptive and at the same time point out that older people should be selected carefully with an eye on sarcopenia. This means: muscle protection belongs in the plan from the start.
DOI: 10.1111/dom.15728These medications are prescription-only and belong in medical care. Side effects mainly concern the gastrointestinal area, for example nausea, a feeling of fullness or constipation. Before a prescription, the benefit, risks, contraindications and personal situation belong reviewed. This article serves for information and replaces no medical examination. Please never obtain such medications without a medical prescription and monitoring. Which side effects can occur is covered in the article on side effects of the weight-loss injection.
The injection as a tool, not a replacement
Why does the injection have such a strong effect at all? Because it targets a real lever. In many people with overweight, appetite and satiety regulation has slipped out of balance. Hunger reports too often, satiety too seldom or too late. The injection can amplify this disturbed signal from outside. Why this regulation can tip over in the first place is explored in the article on appetite, hunger and satiety.
This is also why, in my view, the injection fits best into an overall picture rather than replacing it. Where insulin resistance slows weight loss, where sleep and stress throw the hunger system off, there it is worth working on the causes alongside the treatment. And anyone who would rather support the pathway by natural means first will find approaches in the article on boosting GLP-1 naturally.
The question is rarely whether the injection has an effect. The more interesting question is what you use it for. As a shortcut meant to fix everything alone, it often disappoints. As a strong tailwind that creates room for new habits, it can be a sensible building block.
Conventional medicine gets a lot right here when it checks clear indications and monitors the treatment closely, which is sensible and important. What an integrative view can add is attention to the surroundings: the hormonal and metabolic steering of weight, muscle preservation, sleep and the causes. Our work at ViveCura moves at the intersection of the three areas that define the practice: physical health and metabolism, mental health and a conscious, healthy lifestyle.
And now you know why the weight-loss injection is no foreign-body trick. It speaks the language of your own body, only louder and longer. What comes of it is decided not by the needle alone, but by what you build around it.
Frequently asked questions
How does the weight-loss injection work in the body?
The weight-loss injection mimics GLP-1, a natural gut hormone released after eating. It acts in several places at once: in the brain on the appetite and satiety centres, via the vagus nerve, on slowed stomach emptying, and on a glucose-dependent improvement of the insulin and glucagon response. Hunger falls, satiety lasts longer. This can lead to reduced food intake and weight loss.
How does Ozempic or semaglutide work?
Ozempic contains the active ingredient semaglutide, a GLP-1 receptor agonist. It binds to the same receptors as the body's own GLP-1 and is modified so that it escapes rapid breakdown by the enzyme DPP-4. This keeps it active steadily across the week. In a large randomised trial with almost 2000 people, participants on semaglutide lost about 15 percent of their body weight on average.
Is GLP-1 something unnatural or foreign to the body?
No. GLP-1 is a hormone the body makes itself. It is produced in special cells of the gut lining and released after every meal. The weight-loss injection invents no new trick, it amplifies a pathway the body already uses. The pharmacological trick is to protect the molecule from rapid natural breakdown so that it can stay active long enough.
What is the difference between Ozempic, Wegovy and Mounjaro?
Ozempic and Wegovy both contain the active ingredient semaglutide, a pure GLP-1 receptor agonist, at different approvals and doses. Mounjaro contains tirzepatide, which docks onto two receptors at once, GLP-1 and GIP. This dual point of attack may amplify the effect on weight and metabolism further. All three are prescription-only.
How much weight can you lose with the injection?
In the large STEP 1 trial with semaglutide, the average weight loss after 68 weeks was about 15 percent, compared with roughly 2 percent on placebo. One in two treated people lost at least 15 percent. With tirzepatide the effects in the SURMOUNT-1 trial were even greater. Results vary widely between individuals and also depend on diet, exercise and support.
Why does the injection slow stomach emptying?
GLP-1 physiologically slows the speed at which the stomach passes its contents to the intestine. If the food stays longer in the stomach, the feeling of fullness lasts longer and blood sugar rises more gently after eating. The weight-loss injection amplifies this effect. This explains part of the reduced food intake, but it can also trigger nausea or a feeling of fullness.
Does the weight come back after stopping?
Often yes, at least in part. In the follow-up to the STEP 1 trial, participants regained about two-thirds of the lost weight one year after stopping. This is not a personal failure, it points to obesity being a chronic condition. The effect lasts as long as the treatment lasts. That is why building solid foundations and having medical guidance matter so much.
Do I lose muscle on the weight-loss injection?
With any larger weight loss, part of the loss also comes from lean mass, and that applies to the injection too. A recent review classifies this loss as largely adaptive, meaning within the expected range for weight reduction. The topic matters above all in older people. Strength training and sufficient protein intake can help protect the muscles during treatment.
Is the weight-loss injection a miracle cure?
No. It is an effective tool with a clear evidence base, but not something that runs by itself. It is prescription-only and belongs in medical care. Side effects are common, above all in the gastrointestinal area. Without the foundations of nutrition, muscle building and sleep, success often stays tied to the medication. The injection makes sense for the right people, embedded in an overall concept.
Who is the weight-loss injection even suitable for?
This is always an individual medical decision. In principle these medications are aimed at people with marked overweight or overweight plus a weight-related coexisting condition. Before a prescription, the benefit, risks, contraindications and personal situation belong reviewed. The injection replaces neither a medical examination nor engagement with the underlying causes of the weight.
Read on in the Weight Guide
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183 [RCT, n=1961]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038 [RCT, n=2539]
- Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. DOI: 10.1016/j.molmet.2019.09.010 [Review]
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439. DOI: 10.1152/physrev.00034.2006 [Review]
- Drucker DJ, Holst JJ. The expanding incretin universe: from basic biology to clinical translation. Diabetologia. 2023;66(10):1765-1779. DOI: 10.1007/s00125-023-05906-7 [Review]
- van Bloemendaal L, IJzerman RG, Ten Kulve JS, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63(12):4186-4196. DOI: 10.2337/db14-0849 [RCT, n=48]
- Krieger JP. Intestinal glucagon-like peptide-1 effects on food intake: Physiological relevance and emerging mechanisms. Peptides. 2020;131:170342. DOI: 10.1016/j.peptides.2020.170342 [Review]
- Moiz A, Filion KB, Tsoukas MA, et al. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. Am J Med. 2025;138(6):934-940. DOI: 10.1016/j.amjmed.2025.01.021 [Review]
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. DOI: 10.1111/dom.14725 [RCT, n=327]
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. DOI: 10.1001/jama.2023.24945 [RCT, n=670]
- Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26 Suppl 4:16-27. DOI: 10.1111/dom.15728 [Review]